0
New sequencing studies shed more light on the B.1.1.7 SARS-CoV-2 variant
Two new studies have shed light on the B.1.1.7 variant, suggesting that while it is more transmissible, it does not…
Browsing: Disease Area
0
X-rays and artificial intelligence offer a potential diagnostic tool for COVID-19
Researchers from the Universidade Federal do Ceará, Instituto Federal do Ceará and Universidade de Fortaleza (all Fortaleza, Brazil) report on…
0
nAbbing SARS-CoV-2 variants
New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them. With the COVID-19 pandemic on its third wave in some…
0
What effect will SARS-CoV-2 variants have on vaccine efficacy?
The ‘inevitable’ domination of novel SARS-CoV-2 variants from Brazil, South Africa and the UK could result in less effective COVID-19…
0
Intellectual – not physical – disability is the second greatest predictor of COVID-19 mortality
New research confirms the suspicions of many caregivers around the globe: those with intellectual disabilities are at a vastly increased risk of catching and dying from…
0
How effective are the COVID-19 vaccines for those who are immunocompromised?
Up to 5000 immunocompromised people from across the UK are set to be vaccinated as part of the Octave study…
0
The impact of the first dose of the COVID-19 vaccines
The first national population-level study has shed light on the effect of the first dose of the COVID-19 vaccine. The…
0
One drug to rule them all?
Thapsigargin, a promising broad-spectrum antiviral, has proven effective for use against SARS-CoV-2, as well as the influenza A and respiratory…
0
Natural immunity to COVID-19: how long and how strong?
Two recent papers from Public Health England (PHE; London, UK) and Rockefeller University (NY, USA) have shed new light on the duration and quality of protection provided…
0
A nasal spray a day could keep COVID-19 away
Hands, face, space. These are the three tools available to everyday citizens to prevent the spread of COVID-19; the simple…